This compound is primarily utilized in the field of targeted protein degradation, specifically in the development of PROTACs (Proteolysis Targeting Chimeras). It serves as a BET-binding moiety, enabling the selective targeting of BET family proteins, which are involved in regulating gene expression. By incorporating this moiety into PROTAC molecules, researchers can design compounds that recruit E3 ubiquitin ligases to BET proteins, leading to their ubiquitination and subsequent degradation by the proteasome. This approach is particularly valuable in cancer research, as BET proteins play a critical role in the growth and survival of certain cancer cells. The application of this compound allows for the exploration of novel therapeutic strategies aimed at disrupting oncogenic signaling pathways and inhibiting tumor progression.